IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2603
+0.0058 (2.28%)
At close: Feb 19, 2026, 4:00 PM EST
0.2581
-0.0022 (-0.85%)
Pre-market: Feb 20, 2026, 8:49 AM EST
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$15,800
Profits / Employee
-$92,086
Market Cap
24.94M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2025 | 70 | 3 | 4.48% | 70 | 0 |
| Mar 31, 2024 | 67 | 6 | 9.84% | 67 | 0 |
| Mar 31, 2023 | 61 | 9 | 17.31% | 61 | 0 |
| Mar 31, 2022 | 52 | 2 | 4.00% | 52 | 0 |
| Mar 31, 2021 | 50 | 0 | - | 50 | 0 |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Barinthus Biotherapeutics | 105 |
| Boundless Bio | 64 |
| Evaxion | 46 |
| Senti Biosciences | 34 |
| Daré Bioscience | 23 |
| Skye Bioscience | 16 |
| Rallybio | 15 |
| Neuphoria Therapeutics | 8 |
IGC News
- 3 days ago - IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - Accesswire
- 8 days ago - IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets - Accesswire
- 10 days ago - IGC Pharma Announces Equity Research Update by Alliance Global Partners - Accesswire
- 11 days ago - IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center - Accesswire
- 18 days ago - IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation - Accesswire
- 4 weeks ago - IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York - Accesswire
- 5 weeks ago - IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia - Accesswire
- 6 weeks ago - IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability - Accesswire